Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit
This article was originally published in The Tan Sheet
Executive Summary
Orlistat's benefit in an over-the-countersetting is questionable, but the safety of the weight-loss drug creates a risk/benefit ratio in favor of nonprescription use, an FDA advisory panel expressed in an 11-3 vote Jan. 23
You may also be interested in...
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed
Xenical Off-The-Market Switch Sought By Public Citizen
Public Citizen is calling for prescription weight-loss drug Xenical (120 mg orlistat) to be pulled from the market days after FDA issued an "approvable" letter for an OTC version
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription